DBV Technologies (DBV) Registration filing summary

Company overview and business model

• Clinical-stage specialty biopharmaceutical company developing Viaskin, a novel epicutaneous immunotherapy platform for food allergies, especially in children.

• Lead product candidate Viaskin Peanut has completed multiple Phase 2 and Phase 3 trials for peanut allergy in children, with ongoing and planned additional studies.

• Pipeline includes earlier-stage programs for Viaskin Milk and Eosinophilic Esophagitis.

• Incorporated in France, with shares listed on Euronext Paris and ADSs on Nasdaq Capital Market.

Financial performance and metrics

• As of April 7, 2025, outstanding share capital consisted of 136,948,872 issued ordinary shares, fully paid, with a nominal value of €0.10 per share.

• The company qualifies as a "smaller reporting company" under U.S. securities regulations, allowing for scaled disclosures.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of up to 289,013,065 Resale Shares by selling shareholders; all proceeds go to the selling shareholders.